TMS vs ECT for Depression: How Patients and Caregivers Can Compare Two Neuromodulation Options

The short answer

TMS (transcranial magnetic stimulation) and ECT (electroconvulsive therapy) are both neuromodulation treatments used for depression, but they differ in how they are delivered and what a treatment course involves. TMS is a noninvasive, office-based therapy that uses repeated magnetic pulses to stimulate targeted brain circuits involved in mood regulation. It does not require anesthesia, and patients remain awake during sessions. ECT uses a brief, controlled electrical stimulation while the patient is under general anesthesia, and it is typically reserved for severe or treatment-resistant depression. Both approaches are considered when standard treatments such as medications and psychotherapy have not provided adequate relief. The choice between them is not a simple preference: it depends on symptom severity, medical history, urgency of relief needed, and a thorough evaluation by a qualified clinician. This article explains what the evidence supports about each option, practical differences in treatment schedules and side effects, and questions you can bring to a consultation. It cannot tell you which treatment is right for you or a loved one.^{[source][source][source]}

What the evidence supports

TMS is described by the National Institute of Mental Health as a noninvasive therapy that uses repeated magnetic pulses to stimulate targeted brain circuits. The first rTMS device was FDA-cleared in 2008 for depression after inadequate response to at least one antidepressant in the current episode. Sessions are typically office-based without anesthesia, lasting approximately 3 to 40 minutes, with a typical course of five sessions per week for four to six weeks; accelerated protocols can differ. Common short-term effects include scalp discomfort, facial or jaw muscle sensations, mild headache, and brief lightheadedness or dizziness. Seizure is possible but uncommon when expert safety guidance is followed.^[source]

A consensus statement from the National Network of Depression Centers rTMS Task Group and the American Psychiatric Association Council on Research reviewed adult major-depressive-disorder literature through 2016 and provides clinical implementation recommendations. It supports structured pre-treatment evaluation rather than self-selection: screening should consider seizure history, neurologic history, medicines or substances that may alter seizure threshold, sleep deprivation, and other relevant medical factors. It describes determining an individual motor threshold and treatment location, and it warns about ferromagnetic or magnet-sensitive material near the head and neck and certain implanted devices. This source supports patient-facing explanations of why a consultation asks detailed safety questions and why protocol settings are individualized. It does not establish that every listed risk is an absolute contraindication for every modern device, does not replace current device labeling, and does not authorize diagnosis, medication changes, or personalized treatment selection in public content.^[source]

A 2019 review in Cureus describes TMS as a noninvasive technique that uses brief magnetic pulses applied to the brain, with repetitive TMS (rTMS) delivering pulses in a repetitive fashion. It notes that TMS does not require craniotomy or seizure induction to stimulate nerve cells. The review reports that response rates to TMS range between 50% and 55%, and remission rates range between 30% and 35% in patients with major depression, though it also notes that some randomized trials have shown outcomes similar to placebo in certain populations. The review states that TMS is generally well tolerated, with common side effects including transient headaches, scalp tingling, and rare seizure activity. It emphasizes that patient compliance may be affected because TMS requires frequent clinic visits.^[source]

The FDA's Class II special-controls guidance describes an rTMS system as an external electromagnetic device that delivers repetitive pulsed magnetic fields to activate neurons within a limited cortical volume without intentionally inducing a seizure. It identifies important risks and controls, including selecting the correct patient population, ineffective treatment, seizure, scalp discomfort or burn, effects on other medical devices, hearing effects, electrical hazards, and electromagnetic interference. It also emphasizes labeling, trained use, repeatable coil positioning, and patient/device-specific contraindications and warnings. This guidance is authoritative for the covered device class and terminology, but it must not be used to claim that an unspecified device, indication, accelerated protocol, or patient is currently cleared or appropriate without current device labeling.^[source]

ECT has been used to treat psychiatric symptoms for nearly 100 years and is described by UT Health San Antonio as a safe and highly effective treatment for severe, treatment-resistant depression. It can also treat symptoms of schizophrenia and bipolar disorder. ECT is performed while patients are comfortably asleep under general anesthesia in an outpatient procedure suite, and they are closely monitored until they are ready to leave, usually within 2-3 hours after the procedure. Note that UT Health San Antonio's ECT service is currently on hold with no anticipated restart date at that specific clinic, though this does not reflect availability at other facilities.^[source]

Practical considerations

The practical differences between TMS and ECT shape what a treatment course looks like for patients and caregivers. TMS is typically delivered in an outpatient office setting without anesthesia or sedation. Patients remain awake and can drive themselves to and from appointments and return to usual activities immediately after each session. A typical course involves daily sessions five days per week for several weeks. ECT requires general anesthesia and a recovery period, so patients need someone to accompany them and cannot drive themselves home. ECT sessions are usually scheduled less frequently than TMS sessions, but each visit involves more preparation and monitoring time.^{[source][source]}

Side effect profiles also differ in ways that matter for daily life. TMS is generally well tolerated and does not cause sedation or cognitive impairment. The most common side effects are mild scalp discomfort at the stimulation site and headache during or shortly after treatment; these are typically transient and resolve with continued treatment. Serious adverse events are rare. ECT's side effects can include confusion and memory changes, which patients should discuss with their treatment team. Both treatments carry a risk of seizure, though the risk with TMS is exceedingly low when safety guidelines are followed.^{[source][source]}

Candidacy screening is a critical step for both treatments. For TMS, screening considers seizure history, neurologic history, medicines or substances that may alter seizure threshold, and the presence of ferromagnetic or magnet-sensitive material near the head and neck or certain implanted devices. Patients with any type of non-removable metal in their heads (with the exception of braces or dental fillings) may not be able to receive TMS. For ECT, the pre-treatment evaluation focuses on anesthesia safety, cardiovascular health, and other medical conditions that could affect the procedure. Both pathways require a comprehensive evaluation to confirm the diagnosis, review prior treatment history, and assess appropriateness.^{[source][source]}

Limits and responsible use

This article is educational and cannot determine whether TMS or ECT is appropriate for any individual. It does not replace a comprehensive evaluation by a qualified clinician who can review your specific medical and psychiatric history. Response rates and side effect profiles vary by patient, device, protocol, and clinical setting. Some sources cited here are several years old, and device labeling and clinical practice can change. Always discuss treatment options with your care team and refer to current device labeling and clinical guidance for the most up-to-date information.^{[source][source]}

Frequently Asked Questions

What is the main difference between TMS and ECT for depression?

TMS is a noninvasive, office-based therapy that uses repeated magnetic pulses to stimulate targeted brain circuits without anesthesia, while ECT uses a brief, controlled electrical stimulation while the patient is under general anesthesia. TMS is typically used for treatment-resistant depression when medications and therapy have not provided adequate relief, and ECT is generally reserved for severe or treatment-resistant depression. The choice depends on symptom severity, medical history, urgency of relief needed, and a thorough evaluation by a qualified clinician.

Does TMS require anesthesia or a hospital stay?

No. TMS is typically delivered in an outpatient office setting without anesthesia or sedation. Patients remain awake during sessions and can drive themselves to and from appointments and return to usual activities immediately after each session. A typical course involves daily sessions five days per week for several weeks, but accelerated protocols can differ.

What are the common side effects of TMS and ECT?

For TMS, the most common side effects are mild scalp discomfort at the stimulation site and headache during or shortly after treatment; these are typically transient and resolve with continued treatment. Serious adverse events are rare. ECT's side effects can include confusion and memory changes, which patients should discuss with their treatment team. Both treatments carry a risk of seizure, though the risk with TMS is exceedingly low when safety guidelines are followed.

Who may not be able to receive TMS?

Screening for TMS considers seizure history, neurologic history, medicines or substances that may alter seizure threshold, and the presence of ferromagnetic or magnet-sensitive material near the head and neck or certain implanted devices. Patients with any type of non-removable metal in their heads (with the exception of braces or dental fillings) may not be able to receive TMS. A comprehensive evaluation is needed to confirm the diagnosis, review prior treatment history, and assess appropriateness.

How do I decide between TMS and ECT?

This article cannot tell you which treatment is right for you or a loved one. The decision depends on symptom severity, medical history, urgency of relief needed, and a thorough evaluation by a qualified clinician. Consider asking your care team: What makes one option more suitable than the other for my situation? What does the pre-treatment evaluation involve? What side effects should I watch for, and how are they managed? How will my response be monitored during treatment? What happens if the first treatment course does not provide adequate relief? What support is available for scheduling and transportation?

References

1. Transcranial Magnetic Stimulation (TMS) | McGovern Medical School — med.uth.edu
2. APA and NNDC consensus recommendations for clinical rTMS in major depressive disorder — pmc.ncbi.nlm.nih.gov
3. Use of Transcranial Magnetic Stimulation for Depression – PMC — pmc.ncbi.nlm.nih.gov
4. Non-Invasive Procedures for Psychiatric Conditions | UT Health Physicians — uthscsa.edu
5. FDA Class II special controls for rTMS systems used for major depressive disorder — www.fda.gov
6. NIMH brain stimulation therapies: rTMS patient evidence summary — www.nimh.nih.gov
7. Transcranial Magnetic Stimulation (TMS) – Treatment For Depression | VA Montana Health Care | Veterans Affairs — www.va.gov